Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Belumosudil
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Sanofi
Deal Size : Not Applicable
Deal Type : Not Applicable
Meiji Seika Launches REZUROCK® Tablets in Japan for Chronic Graft-Versus-Host Disease
Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).
Brand Name : Rezurock
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 22, 2024
Lead Product(s) : Belumosudil
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Sanofi
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Belumosudil
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Sanofi
Deal Size : Not Applicable
Deal Type : Not Applicable
Meiji Seika Receives Approval for REZUROCK® in Japan for Chronic Graft-Versus-Host Disease
Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).
Brand Name : Rezurock
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 26, 2024
Lead Product(s) : Belumosudil
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Sanofi
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Belumosudil
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Sanofi
Deal Size : Not Applicable
Deal Type : Not Applicable
New Drug Application for ME3208 Submitted in Japan for Chronic Graft-Versus-Host Disease
Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).
Brand Name : Rezurock
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 27, 2023
Lead Product(s) : Belumosudil
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Sanofi
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Belumosudil
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Sanofi
Deal Size : Not Applicable
Deal Type : Not Applicable
ME3208 Receives Orphan Drug Designation in Japan for Chronic Graft-Versus-Host Disease
Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).
Brand Name : Rezurock
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 24, 2023
Lead Product(s) : Belumosudil
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Sanofi
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Monoclonal Antibody
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Foundation for Biomedical Research and Innovation at Kobe
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : A novel anti-PD-1 agonist monoclonal antibody, which inhibits the function of PD-1 (anti-PD-1 blocking antibodies) leading in enhanced anti-tumor immunity.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 16, 2023
Lead Product(s) : Monoclonal Antibody
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Foundation for Biomedical Research and Innovation at Kobe
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ME3183
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In non-clinical studies, ME3183, a selective phosphodiesterase-4 (PDE4) inhibitor, showed greater anti-inflammatory effect and its inhibitory effect on TNF-α production was approximately 30-fold greater than the existing orally-available PDE4 inhibitor ...
Brand Name : ME3183
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 07, 2022
Lead Product(s) : ME3183
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ME3183
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ME3183 is an orally-available and selective inhibitor for phosphodiesterase 4 (PDE4) discovered by Meiji. In the study, ME3183 has been shown to be safe and well-tolerated across the doses tested.
Brand Name : ME3183
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 24, 2021
Lead Product(s) : ME3183
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Intas Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Intas Enters License Agreement with Meiji and Dong Commercialize DMB-3115
Details : Under the terms of the agreement, Intas was granted the exclusive license rights to market DMB-3115 worldwide, excluding Japan, Korea and certain countries in Asia.
Brand Name : DMB-3115
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 21, 2021
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Intas Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Dong-A Socio Holdings
Deal Size : Not Applicable
Deal Type : Not Applicable
Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115
Details : A single subcutaneous injection of DMB3115 in healthy volunteers was well tolerated. The reported adverse events corresponded with the known safety profile of ustekinumab.
Brand Name : DMB-3115
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 21, 2021
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Dong-A Socio Holdings
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Safinamide Mesylate
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Eisai will take over by transfer the manufacturing and marketing approval of Equfina from Meiji. Eisai, as the manufacturer and distributor of Equfina in Japan, will continue to provide information on the proper usage of Equfina.
Brand Name : Equfina
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 07, 2020
Lead Product(s) : Safinamide Mesylate
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?